Co-Administration of Vonoprazan, Not Tegoprazan, Affects the Pharmacokinetics of Atorvastatin in Healthy Male Subjects

Hwang, Sejung; Ko, Ji Hyun; Lee, Heechan; Kim, Seokuee; Kim, Bongtae; Song, Geun Seog; Kim, Jung-Ryul

doi:10.3389/fphar.2021.754849

Cited by 3 publications

(1 citation statement)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Compared to conventional proton pump inhibitors (PPIs), P-CAB competes with potassium to inhibit H + /K + -ATPase and does not require acid-induced activation [3]. While PPIs typically require approximately 3-5 days to exert a maximal effect on gastric acid secretion, P-CABs produce strong and long-lasting inhibitory activity from the first dose [4][5][6].…”

Section: Introductionmentioning

confidence: 99%

Novel Cocrystals of Vonoprazan: Machine Learning-Assisted Discovery

Lee

Kim

et al. 2022

Pharmaceutics

View full text Add to dashboard Cite

Vonoprazan (VPZ) is the first-in-class potassium-competitive acid blocker (P-CAB), and has many advantages over proton pump inhibitors (PPIs). It is administered as a fumarate salt for the treatment of acid-related diseases, including reflux esophagitis, gastric ulcer, and duodenal ulcer, and for eradication of Helicobacter pylori. To discover novel cocrystals of VPZ, we adopted an artificial neural network (ANN)-based machine learning model as a virtual screening tool that can guide selection of the most promising coformers for VPZ cocrystals. Experimental screening by liquid-assisted grinding (LAG) confirmed that 8 of 19 coformers selected by the ANN model were likely to create new solid forms with VPZ. Structurally similar benzenediols and benzenetriols, i.e., catechol (CAT), resorcinol (RES), hydroquinone (HYQ), and pyrogallol (GAL), were used as coformers to obtain phase pure cocrystals with VPZ by reaction crystallization. We successfully prepared and characterized three novel cocrystals: VPZ–RES, VPZ–CAT, and VPZ–GAL. VPZ–RES had the highest solubility among the novel cocrystals studied here, and was even more soluble than the commercially available fumarate salt of VPZ in solution at pH 6.8. In addition, novel VPZ cocrystals had superior stability in aqueous media than VPZ fumarates, demonstrating their potential for improved pharmaceutical performance.

show abstract

Section: Introductionmentioning

confidence: 99%

Novel Cocrystals of Vonoprazan: Machine Learning-Assisted Discovery

Lee

Kim

et al. 2022

Pharmaceutics

View full text Add to dashboard Cite

show abstract

Potassium-competitive Acid Blockers: Current Clinical Use and Future Developments

Scarpignato,

Hunt

2024

Curr Gastroenterol Rep

View full text Add to dashboard Cite

Purpose of the Review Acid suppression with proton pump inhibitors (PPIs) represents the standard of care in the treatment of acid-related diseases. However, despite their effectiveness, PPIs display some intrinsic limitations, which underlie the unmet clinical needs that have been identified over the past decades. The aims of this review are to summarize the current status and future development of the new class of antisecretory drugs (potassium-competitive acid blockers, P-CABs) that have recently been introduced into medical practice. Recent Findings Over the past decades, clinical needs unmet by the current acid suppressants have been recognized, especially in the management of patients with GERD, Helicobacter pylori infection and NSAID-related peptic ulcer. The failure to address these needs is mainly due to their inability to achieve a consistent acid suppression in all patients and, particularly, to control nighttime acidity. It was then realized that an extended duration of acid suppression would exert additional benefits. The available data with P-CABs show that they are able to address these unmet clinical needs. Summary Four different P-CABs (vonoprazan, tegoprazan, fexuprazan and keverprazan) are currently available. However, only two of them are approved outside Asia. Vonoprazan is available in North, Central and South America while tegoprazan is marketed only in Latin American countries. Two other compounds (namely linazapran glurate and zestaprazan) are presently under clinical development. While clinical trials on GERD have been performed with all P-CABs, only vonoprazan and tegoprazan have been investigated as components of Helicobacter pylori eradication regimens. The available data show that—in the above two clinical indications—P-CABs provide similar or better efficacy in comparison with PPIs. Their safety in the short-term overlaps that of PPIs, but data from long-term treatment are needed.

show abstract

Optimal Use of Proton Pump Inhibitors and Potassium-competitive Acid Blockers

Park

2023

Korean J Helicobacter Up Gastrointest Res

View full text Add to dashboard Cite

A variety of proton pump inhibitors (PPIs) have been developed in Korea since the introduction of omeprazole (the first PPI) in 1989. PPIs have served as the basic therapeutic approach for the management of gastric acid-related diseases for 30 years and remain among the most widely used drugs. Recently, potassium-competitive acid blockers (PCABs) have been developed both in Korea and abroad, demonstrating superior or non-inferior effects compared to existing PPIs in treating gastroesophageal reflux disease or <i>Helicobacter pylori</i> eradication, among others. Indications vary based on the various types and dosages of PPIs and PCABs, and several factors, including patients’ underlying disease, safety profile, particularly with regard to drug-drug interactions, and types of formulations of PPIs and PCABs need to be considered prior to prescribing these medications. In this article, we discuss the criteria for reimbursement of various PPIs and PCABs in Korea, along with considerations for prescribing these drugs based on patients’ underlying diseases.

show abstract

Co-Administration of Vonoprazan, Not Tegoprazan, Affects the Pharmacokinetics of Atorvastatin in Healthy Male Subjects

Cited by 3 publications

References 26 publications

Novel Cocrystals of Vonoprazan: Machine Learning-Assisted Discovery

Novel Cocrystals of Vonoprazan: Machine Learning-Assisted Discovery

Potassium-competitive Acid Blockers: Current Clinical Use and Future Developments

Optimal Use of Proton Pump Inhibitors and Potassium-competitive Acid Blockers

Contact Info

Product

Resources

About